Ropes & Gray represented Sanofi in connection with MapLight Therapeutics’ oversubscribed $372.5 million Series D financing. MapLight is a biotechnology company that leverages its multi-pronged Optogenetics, Transcriptomics, and STARmap drug discovery platforms to develop therapeutics for multiple CNS indications. Other investors participating in the financing included Forbion, Life Sciences at Goldman Sachs Alternatives, accounts advised by T. Rowe Price Investment Management, Inc., Avego BioScience Capital, and funds managed by Novo Holdings, 5AM Ventures, Blue Owl Healthcare Opportunities, and others.
The Ropes & Gray team included venture capital and emerging companies associates Daniel Freshman and Derek Mubiru, partner Rajarshi Banerjee, and litigation & enforcement partner Brendan Hanifin.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.